Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Equity Ratio (2017 - 2025)

Historic Equity Ratio for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to 0.95.

  • Dianthus Therapeutics' Equity Ratio fell 78.79% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year decrease of 78.79%. This contributed to the annual value of 0.94 for FY2024, which is 12.26% up from last year.
  • Dianthus Therapeutics' Equity Ratio amounted to 0.95 in Q3 2025, which was down 78.79% from 0.93 recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year Equity Ratio high stood at 0.97 for Q1 2024, and its period low was 0.78 during Q2 2023.
  • Over the past 4 years, Dianthus Therapeutics' median Equity Ratio value was 0.93 (recorded in 2025), while the average stood at 0.53.
  • The largest annual percentage gain for Dianthus Therapeutics' Equity Ratio in the last 5 years was 53769.16% (2023), contrasted with its biggest fall of 20087.62% (2023).
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Equity Ratio stood at 0.53 in 2022, then surged by 276.32% to 0.94 in 2023, then grew by 0.12% to 0.94 in 2024, then grew by 0.41% to 0.95 in 2025.
  • Its last three reported values are 0.95 in Q3 2025, 0.93 for Q2 2025, and 0.94 during Q1 2025.